Schonfeld Strategic Advisors’s Ambrx Biopharma Inc AMAM Stock Holding History

Schonfeld Strategic Advisors’s Portfolio AMAM Stock Details AMAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-263,743	Closed	-$3.76M	–	2519
2023 Q4	$3.76M	Buy	+263,743	New	+$3M	0.02%	593
2023 Q3	–	Sell	-98,600	Closed	-$1.62M	–	2456
2023 Q2	$1.62M	Buy	98,600 +20,400	+26%	+$257K	0.01%	818
2023 Q1	$698K	Buy	+78,200	New	+$393K	0.01%	1069

Schonfeld Strategic Advisors's AMAM Position: Q1 2024 in Review

Schonfeld Strategic Advisors sold out of Ambrx Biopharma Inc (AMAM) in Q1 2024, closing a stake of 263,743 shares — an estimated $3.76M sold.

Schonfeld Strategic Advisors first reported a position in AMAM in Q1 2023 and held it in 3 quarters. The position peaked at $3.76M in Q4 2023. 0 funds tracked by Wall St. Rank hold AMAM as of Q1 2024.

Schonfeld Strategic Advisors reported no remaining Ambrx Biopharma Inc position as of Q1 2024 after selling out during the quarter.
Schonfeld Strategic Advisors sold 263,743 Ambrx Biopharma Inc shares in Q1 2024, an estimated $3.76M.
Schonfeld Strategic Advisors first reported a position in Ambrx Biopharma Inc in Q1 2023 and held it in 3 quarters.
Schonfeld Strategic Advisors's Ambrx Biopharma Inc position peaked at $3.76M in Q4 2023.
0 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q1 2024.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2024, filed 15 May 2024.